Clinical Trial Update: Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing lapatinib alone versus lapatinib with capecitabine in HER2-positive metastatic gastroesophageal cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer

Drugs mentioned

• Tykerb (lapatinib)
• Xeloda (capecitabine)

Snippet

Sponsor: National Center for Tumor Diseases, Heidelberg | Conditions: GastroEsophageal Cancer | Phase 2 | Status: TERMINATED